Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22666390 | 1.00 | SLC6A4 (0.42) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL22666434 | 1.00 | SLC6A4 (0.42) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL16406055 | 0.90 | SLC6A4 (0.45) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL15177888 | 0.90 | SLC6A4 (0.42) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL19866643 | 0.84 | HTR2A (0.43) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL19645410 | 0.84 | SLC6A2 (0.38) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL16406052 | 0.80 | HTR2A (0.46) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL19857249 | 0.80 | HCRTR2 (0.36) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL22666391 | 0.80 | HCRTR2 (0.36) | SLC6A4SLC6A2CCR2HTR2AHTR2C | |
| SCHEMBL15213356 | 0.80 | HCRTR2 (0.36) | SLC6A4SLC6A2CCR2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| CN-113727962-A | Methods and compounds for preparing orexin-2 receptor antagonists and lebereproduction with reduced impurities | 卫材R&D管理有限公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2020230800-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2020-11-19 | — | — | WO | disclosed |
| EP-2814798-B1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| EP-2814798-B1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-20180044285-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044285-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044285-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9828336-B2 | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| WO-2013123240-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD (JP) | 2013-08-22 | — | — | WO | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | HCRTR2, HCRTR1, MCHR2 | SLC6A4 3005/4885SLC6A2 1060/4885CCR2 538/4885 |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | SLC6A4 370/4885SLC6A2 331/4885CCR2 267/4885 |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | HCRTR2, HCRTR1, NPY2R | SLC6A4 341/4885SLC6A2 233/4885CCR2 869/4885 |
| US-20180044285-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | SLC6A4 341/4885SLC6A2 233/4885CCR2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.